Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity
Related Experiment Video
Updated: Sep 25, 2025
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Hanane Chamma1, Isabelle K Vila1, Clara Taffoni1
1Institut de Génétique Humaine, CNRS, Université de Montpellier, Molecular Basis of Inflammation Laboratory, Montpellier, France.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is a cancer of poor prognosis that presents with a dense desmoplastic stroma that contributes to therapeutic failure. PDAC patients are mostly unresponsive to immunotherapy. However, hopes to elicit response to immunotherapy have emerged with novel strategies targeting the Stimulator of Interferon Genes (STING) protein, which is a major regulator of tumor-associated inflammation. Combination of STING agonists with conventional immunotherapy approaches has proven to potentiate therapeutic benefits in several cancers. However, recent data underscore that the output of STING activation varies depending on the cellular and tissue context. This suggests that tumor heterogeneity, and in particular the heterogeneity of the tumor microenvironment (TME), is a key factor determining whether STING activation would bear benefits for patients. In this review, we discuss the potential benefits of STING activation in PDAC. To this aim, we describe the major components of the PDAC TME, and the expected consequences of STING activation.
Insights
Stimulator of Interferon Genes (STING) activation shows promise for pancreatic cancer immunotherapy. However, tumor microenvironment heterogeneity may impact treatment effectiveness, requiring careful consideration for patient benefit.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis, often unresponsive to immunotherapy due to its dense desmoplastic stroma.
- The tumor microenvironment (TME) plays a critical role in PDAC progression and therapeutic resistance.
- Stimulator of Interferon Genes (STING) is a key regulator of tumor-associated inflammation, offering potential therapeutic avenues.
Purpose of the Study:
- To explore the potential benefits of STING activation in pancreatic ductal adenocarcinoma.
- To analyze the components of the PDAC tumor microenvironment.
- To predict the consequences of STING activation within the PDAC context.
Main Methods:
- Review of current literature on STING activation in cancer.
- Analysis of PDAC tumor microenvironment characteristics.
- Discussion of the interplay between STING signaling and tumor heterogeneity.
Main Results:
- STING activation can modulate tumor-associated inflammation, potentially enhancing anti-tumor immunity.
- The cellular and tissue context of the TME significantly influences the outcome of STING activation.
- Tumor heterogeneity is a critical factor determining the efficacy of STING-targeted therapies.
Conclusions:
- STING activation presents a promising strategy to overcome immunotherapy resistance in PDAC.
- Understanding PDAC TME heterogeneity is essential for optimizing STING-based therapeutic approaches.
- Further research is needed to tailor STING activation strategies for improved patient outcomes in pancreatic cancer.
Related Concept Videos
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy